Renvela and Hypercalcaemia - a phase IV clinical study of FDA data

Summary:

Hypercalcaemia is reported as a side effect among people who take Renvela (sevelamer carbonate), especially for people who are male, 50-59 old, also take Renagel, and have Hyperparathyroidism.

The phase IV clinical study analyzes which people have Hypercalcaemia when taking Renvela. It is created by eHealthMe based on reports of 10,884 people who have side effects when taking Renvela from the FDA, and is updated regularly.

What is Renvela?

Renvela has active ingredients of sevelamer carbonate. eHealthMe is studying from 10,923 Renvela users. Check the latest studies of Renvela.

What is Hypercalcaemia?

Hypercalcaemia (elevated calcium (ca+) level in the blood) is found to be associated with 1,058 drugs and 1,017 conditions by eHealthMe. Check the latest studies of Hypercalcaemia.

On Aug, 06, 2026

10,884 people reported to have side effects when taking Renvela.
Among them, 26 people (0.24%) have Hypercalcaemia.

Among these 26 people:

What is the gender of people who have Hypercalcaemia when taking Renvela? *

female: 50 %
male: 50 %

What is the age of people who have Hypercalcaemia when taking Renvela? *

What are other drugs people take besides Renvela? *

What are other side effects people have besides Hypercalcaemia? *

Weakness: 7 people, 26.92%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 6 people, 23.08%
Procedural Hypotension: 5 people, 19.23%
High Blood Pressure: 5 people, 19.23%
Diarrhea: 4 people, 15.38%
Nausea And Vomiting: 4 people, 15.38%
Nausea (feeling of having an urge to vomit): 4 people, 15.38%
Metabolic Acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body): 4 people, 15.38%
Haemoglobin Decreased: 4 people, 15.38%
Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 15.38%

What are the existing conditions these people have? *

Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 6 people, 23.08%
Kidney Transplant Rejection: 3 people, 11.54%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 3 people, 11.54%
Multiple Myeloma (cancer of the plasma cells): 2 people, 7.69%
Anaemia (lack of blood): 2 people, 7.69%
Chronic Renal Failure (kidney failure): 2 people, 7.69%
Type 2 Diabetes: 1 person, 3.85%
Dry Eyes (lack of adequate tears): 1 person, 3.85%
Affective Disorder (mental disorder): 1 person, 3.85%
Asthma: 1 person, 3.85%

* Approximation only. Some reports may have incomplete information.

Do you take Renvela and have Hypercalcaemia?

- Check whether Hypercalcaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Renvela:

Renvela (10,923 reports)

Hypercalcaemia treatments and more:

Hypercalcaemia (18,731 reports)

Browse all side effects of Renvela:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypercalcaemia:

Hypercalcaemia (1,058 drugs)

Browse all the conditions that are associated with Hypercalcaemia:

Hypercalcaemia (1,017 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sevelamer carbonate (the active ingredients of Renvela) and Renvela (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.